Radius Business Review Ends In Sale To Investment Funds

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

sold sign
Radius Health was sold to two investment firms • Source: Shutterstock

Five years after launching its sole commercial drug Tymlos (abaloparatide) for osteoporosis, Radius Health, Inc. will be sold to two health care-focused investment firms for approximately $890m, including a contingent value right (CVR). Radius announced the agreement to be acquired by Gurnet Point Capital Limited and Patient Square Capital on 23 June in a transaction that will take the public company private.

The sale follows a nine-month strategic review by the Radius board of directors to explore avenues to maximize shareholder value...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.